ChemGenex completes SPP
Tuesday, 14 October, 2008
ChemGenex Pharmaceuticals [ASX: CXS] has completed its share placement program, raising over $13 million to fund the late-stage development of its omacetaxine candidate for chronic myeloid leukaemia.
15.3 million shares were placed during the program, trading at 85 cents each. During the period of the program, CXS shares traded at a high of 83 cents and a low of 72.5 cents.
All shares on offer were purchased. ChemGenex representatives said they were pleased the placement went so well considering the unstable global financial climate.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
